Throughout her career, Ms. Pike has applied her expertise in economics and statistics to a wide array of health care cases. She has been engaged on more than 25 False Claims Act matters in the pharmaceutical and medical device industries involving allegations of off-label promotion, kickbacks, and unapproved or mislabeled products. She has extensive experience using company transaction and financial data, publicly available Medicare and Medicaid data, and administrative claims data to assess off-label use and reimbursements. Ms. Pike has served as an expert witness on behalf of pharmaceutical and medical device companies in qui tam litigation as well as in presentations to government investigators on issues related to liability and damages in False Claims Act and Anti-Kickback Statute cases.
Ms. Pike also applies statistical and subject matter expertise to assist pharmaceutical manufacturers, distributors, and pharmacies in monitoring controlled substance distribution and in maintaining Effective Controls Against Diversion. She has applied economic theory and empirical estimation methods in a variety of product liability, breach of contract, intellectual property, and transfer pricing engagements, and has developed flexible damages models for real-time use in high-stakes negotiations. She has managed a broad range of health care cases involving analysis of future lost profits; economic analysis of physician payment structures under capitation; studies of the cost effectiveness, budget impacts, and direct and indirect costs of illness associated with a variety of diseases; and pricing analyses for large multinational corporations across numerous industries. Ms. Pike has published numerous articles on related topics in health care economics and clinical journals.